Catalent extends global commercial spray drying capabilities in Europe
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.
Catalent has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, UK facility.
This agreement immediately extends Catalent’s global spray drying offering by making available to Catalent and Catalent’s customers the dedicated use of the existing Niro PSD2 and PSD4 spray driers at the facility. These spray driers are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations as well as a secondary vacuum dryer. Catalent is now able to offer spray drying solutions from early-phase development through clinical supply and all the way to fully scaled-up commercial finished dose form manufacturing in Europe.
Under the terms of this agreement, Catalent will also have access to the facility’s integrated quality control and analytical capabilities with scientific support resources, enabling an end-to-end approach for customers.
“This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site with expertise in commercial-scale spray dried dispersions, which are frequently used today to overcome the solubility challenges with many new medicines,” said Jonathan Arnold, President of Catalent’s Oral Drug Delivery business unit.
“Sanofi Haverhill is our center of excellence for spray drying technology. The site has over a decade of experience in spray drying operations for commercial manufacture. We welcome the relationship with Catalent and are delighted that Catalent is investing in the innovation and resources at our U.K. facility,” said Philippe Clavel, Head of Sanofi Active Ingredient Solutions.
Earlier this year, Catalent announced a $40M investment in its Winchester, Kentucky facility that includes adding commercial-scale spray drying with high-potent handling capabilities, as well as other increases to the site’s capacity and its formulation and controlled-release tablet and capsule manufacturing capabilities. The Winchester facility will work alongside the Sanofi Haverhill facility to enable transfer and scale-up of spray drying programs from Catalent’s specialized early-stage clinical development sites located in San Diego, California and Nottingham, UK.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance